Inflammatory/Angiogenic markers
| Marker (reference range) | Baseline | 12 Weeks | 26 Weeks | 52 Weeks |
| VEGF (pg/mL) (31–86) | ||||
| Subject 1 | 57 | 91 (H) | <31 (L) | 74 |
| Subject 2 | 129 (H) | NA* | <3 1 (L) | 93 (H) |
| FGF2 (pg/mL) (≤6.5) | ||||
| Subject 1 | 1.7 | 5.6 | 8.3 (H) | 45 (H) |
| Subject 2 | 30 (H) | NA* | 22.0 (H) | 19.5 (H) |
| CRP (mg/L) (≤3.0) | ||||
| Subject 1 | 0.6 | 6.6 (H) | 0.7 | 0.5 |
| Subject 2 | 5.6 (H) | 6.4 (H) | 0.8 | 2.2 |
| ESR (mm/hour) (≤20) | ||||
| Subject 1 | 2 | 2 | NA* | 2 |
| Subject 2 | 6 | 6 | 2 | NA* |
| IL-2 (pg/mL) (<38) | ||||
| Subject 1 | <38 | <38 | <38 | <38 |
| Subject 2 | <38 | <38 | <38 | <38 |
| IL-6 (pg/mL) (0.31–5.00) | ||||
| Subject 1 | 3.41 | 1.92 | 2.04 | 2.75 |
| Subject 2 | 1.55 | 0.79 | 1.08 | 0.86 |
| IL-1β (pg/mL) (<3.9) | ||||
| Subject 1 | <3.9 | <3.9 | NA* | <3.9 |
| Subject 2 | <3.9 | <3.9 | <3.9 | <3.9 |
| MPO (AI) (<1.0) | ||||
| Subject 1 | <1.0 | <1.0 | <1.0 | <1.0 |
| Subject 2 | <1.0 | <1.0 | <1.0 | <1.0 |
| TNF-α (pg/mL) (0.56–1.40) | ||||
| Subject 1 | <1 (L) | <1 (L) | <1 (L) | <1 (L) |
| Subject 2 | 1.05 | 1.16 | <1 (L) | 1.3 |
*These data were not collected.
AI, antibody index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; FGF2, fibroblast growth factor 2; H, high; IL, interleukin; L, low; MPO, myeloperoxidase; TNF-α, tumour necrosis factor α; VEGF, vascular endothelial growth factor.